This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Teva Pharmaceutical Industries Ltd.

Drug Names(s): CDP-choline, cytidine-5-diphosphocholine, Somazina, CerAxon

Description: Citicoline is approved in Europe and Japan for use in stroke, head trauma and other neurological disorders. Citicoline is an intermediate in the synthesis of phosphatidylcholine, a cell membrane component. Thus citicoline administration helps to stabilize cell membranes and promotes membrane repair.

Deal Structure: Interneuron (Indevus) and Ferrer
In January 1993, Interneuron entered into an agreement with Ferrer Internacional, granting Interneuron the exclusive right to make, use and sell any products or processes developed under patent rights relating to certain uses of citicoline in exchange for an up-front license fee and royalties based on sales.

In 2002, Interneuron Pharmaceuticals changed its name to Indevus.

Effective January 22, 2004, Indevus entered into a new agreement with Ferrer superseding the January 1993 agreement and covering the development, manufacture, and marketing of citicoline in the U.S. and Canada. Under the terms of the new agreement, Indevus granted Ferrer exclusive rights to the company's patents and know-how related to citicoline. In exchange, Ferrer agreed to assume all future development, manufacturing, and commercialization costs of citicoline. Indevus will receive 50% of all milestone payments made to Ferrer by a third party and royalties on net...See full deal structure in Biomedtracker

Partners: Grupo Ferrer Internacional, S.A. Endo International plc

Citicoline News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug